Market Capitalization (Millions $) |
892 |
Shares
Outstanding (Millions) |
42 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-97 |
Cash Flow (TTM) (Millions $) |
-80 |
Capital Exp. (TTM) (Millions $) |
1 |
Cassava Sciences Inc
Cassava Sciences Inc is a biopharmaceutical company that focuses on developing drugs for the treatment of Alzheimer's disease. The company's primary drug candidate is called PTI-125, which aims to reduce neuroinflammation and improve cognition in Alzheimer's patients. Cassava Sciences also has an extensive pipeline of other candidates targeting various aspects of the disease. The company is dedicated to advancing innovative, science-driven solutions for Alzheimer's, a debilitating neurodegenerative disease that affects millions of people worldwide.
Company Address: 6801 N. Capital of Texas Highway, Building 1; Suite 300 Austin 78731 TX
Company Phone Number: 501-2444 Stock Exchange / Ticker: NASDAQ SAVA
|